Weight loss via GLP-1s like Ozempic ($17.45B in 2024 sales, up 25% YoY) proved even more lucrative than erectile dysfunction, with Ro's GLP-1 sales 3x'ing between January 2023 and August 2024, pushing topline growth to 66% in 2024 (vs 14% in 2023 and 5% in 2022) and lifting average transaction value from ~$93 to ~$134, while Hims & Hers hit 100K GLP-1 members and ~$343M in annualized GLP-1 revenue by the end of 2024
They are used primarily for weight management and the treatment of type 2 diabetes
Patient Perspective Both patients reported satisfaction with their outcomes and remained asymptomatic at follow-up
Neither medication has been studied in breastfeeding populations, meaning individual case decisions depend entirely on clinical judgment and risk-benefit assessment rather than robust trial data
Hypertension in young women: implications of the polycystic ovary syndrome and opportunities for prevention and further research
8.6 Renal Impairment BYETTA is not recommended for use in patients with end-stage renal disease or severe renal impairment (creatinine clearance 7.0% entered a 30-week intervention phase and were randomized to add either BYETTA or insulin lispro to their existing regimen of insulin glargine and metformin
